Disease-A-Month
Volume 55, Issue 7 , Pages 439-470 , July 2009

Clostridium difficile

References 

  1. Centers for Disease Control and Prevention. Clostridium difficile infections. http://www.cdc.gov/ncidod/dhqp/id_cdiff_data.html
  2. Walbrown MA, Aspinall SL, Bayliss NK, et al. Evaluation of Clostridium difficile-associated diarrhea with a drug formulary change in preferred flouroquinolones. J Manag Care Pharm. 2008;14(1):34–40
  3. O'Connor J. C diff—Rise in UK deaths: 72% increase between 2005 and 2006. http://patient-health-education.suite101.com/article.cfm/c_difficile_rise_in_uk_deaths2008;Feb 28, Last accessed 6/24/08
  4. Kyne L. Health care associated costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34:346–353
  5. Scheurer DB, Hicks LS, Cook EF, et al. Short report—Accuracy of ICD-9 coding for Clostridium difficile infections: A retrospective cohort. Epidemiol Infect. 2007;135:1010–1013
  6. Zerey M, Paton BL, Lincourt AE, et al. The burden of Clostridium difficile in surgical patients in the United States. Surg Infect (Larchmt). 2007;8(6):557–566
  7. Deaths involving MRSA and Clostridium difficile continue to rise. Health statistics. Quarterly Spring 2007; Febr 22, 2007. Issued by the Office of National Statistics, London SW1V 2QQ. http://www.statistics.gov.uk/releases.
  8. Fordtran JS. Colitis due to Clostridium difficile toxins: Underdiagnosed, highly virulent, and nosocomial. Proc Bayl Univ Med Cent. 2006;19:3–12
  9. Dramatic rise in C diff deaths (BBC News February 28, 2008). http://news.bbc.co.uk/1/hi/health/7268578.stmLast accessed 8/12/08
  10. Sunenshine RH, McDonald LC. Clostridium difficile-associated disease: New challenges from an established pathogen. Cleve Clin J Med. 2006;73(2):187–197
  11. Friedenberg FK. Clostridium difficile associated disease: Changing epidemiology and treatment options (Medscape Gastroenterology). http://www.medscape.com/viewarticle/563386_printLast accessed 6/25/08
  12. Ashu NJ, Tompkins D, Wilcox MH. Comparative analysis of prevalence, risk factors and molecular epidemiology of antibiotic associated diarrhea due to Clostridium difficile, Clostridium perfringens, and Staphylococcus aureus. J Clin Microbiol. 2006;44:2785–2791
  13. Kuijper EJ, Coignard TP. Emergence of Clostridium difficile associated disease in North America and Europe. Clin Microbiol Infect. 2006;12:2–18
  14. McDonald LC, Kilgore GE, Thomson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433–2441
  15. Jarvis WR. Infection control and changing health care delivery systems. Emerg Infect Dis. 2001;7(2):170–173
  16. Klevens RM, Edwards JR, Richards CL, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Pub Health Rep. 2007;122:160–166
  17. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Cont. 2004;32:470–485
  18. CDC NNIS system. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992-June 2003 (Issued August 2003). Am J Infect Cont. 2003;31:481–498
  19. Edwards JR, Peterson KD, Andrus ML, et al. National Healthcare Safety Network (NHSN) Report (Data summary for 2006, issued 2007). Am J Infect Cont. 2007;35:290–301
  20. Centers for Disease Control and Prevention (CDC). Outline for health care-associated infection surveillance. http://www.cdc.gov/ncidod/dhqp/nhsn+documents.html
  21. Johal SS, Hammond J, Solomon K, et al. Clostridium difficile associated diarrhea in hospitalized patients: Onset in the community and hospital and role of flexible sigmoidoscopy. Gut. 2004;53(;5):673–677
  22. Clostridium difficile. In:  Aberg JA,  Goldman MP,  Gray LD, et al. editor. Infectious Diseases Handbook Including Antimicrobial Therapy & Diagnostic Tests/Procedures. 6th ed.. Hudson, OH: Lexi-Comp; 2005;p. 83–86
  23. Halsey J. Current and future treatment modalities for Clostridium difficile associated disease. Am J Health Syst Pharm. 2008;65:705–715
  24. Drudy D, Harnedy N, Fanning S, et al. Emergence and control of fluoroquinolone resistant, toxin A negative, toxin B positive Clostridium difficile. Infect Cont Hosp Epidemiol. 2007;28(8):932–940
  25. Kim J, Smathers SA, Prasad P, et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics. 2008;122:1266–1270
  26. Moss L. Hospital Clostridium difficile deaths: The patients let down by those they trusted. http://News.scotsman.comAugust 12, 2008. http://news.scotsman.com/latestnews/-Hospital-c-difficile-deaths.4370831.jp
  27. O'Connor J. C diff—Rise in UK deaths: 72% increase between 2005 and 2006. http://patient-health-education.suite101.com/article.cfm/c_difficile_rise_in_uk_deaths2008;Feb 28, Last accessed 6/24/08
  28. Christensen M, Jepsen OB. Reduced rates of hospital acquired UTI in medical patients (Prevalence surveys indicated effect of active infection control programmes). J Hosp Infect. 2001;47:36–40
  29. Provincial Infectious Diseases Advisory Committee (PIDAC). Best practices document for the management of Clostridium difficile in all health care settings. Ministry of Health and Long Term Care. Published December 2004, Revised November 2007.
  30. Nelson RL. Antibiotic treatment for Clostridium difficile associated diarrhea in adults. Cochrane Datatbase Syst Rev. 2008;4
  31. Joint Commission Accreditation Healthcare Organizations (JCAHO). http://www.jointcommission.org/
  32. Boyce JM, Pittet D. Guidelines for Hand Hygiene in Health Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. A report of the CDC. MMWR Morb Mortal Wkly Rep. 2002;51:RR-16
  33. Institute for healthcare improvement. Saving 100,000 lives campaign. http://www.ihi.org
  34. Association for Professionals in Infection Control and epidemiology (APIC). Government advocacy. http://www.apic.org/content/navigationmenu/governmentadvocacy/mandatoryreporting/abouttheissue/about_the_issue.htm
  35. Burke JP. Infection control—A problem for patient safety. N Engl J Med. 2004;348:651–656
  36. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile associated diarrhea. Clin Infect Dis. 2005;41:1254–1260
  37. Cunningham R, Dial S. Is over use of proton pump inhibitors fueling the current epidemic of Clostridium difficile associated diarrhea?. J Hosp Infect. 2008;70(;1):1–6
  38. Aseeri M, Schroeder T, Kramer J, et al. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile associated diarrhea in hospitalized patients. Am J Gastroenterol. 2008;103(;9):2308–2313
  39. Akhtar AJ, Shaheen M. Increasing incidence of Clostridium difficile associated diarrhea in African American and Hispanic patients: Association with the use of proton pump inhibitor therapy. J Natl Med Assoc. 2007;99(5):500–504
  40. Sprague L. Health care-associated infections: is there an end in sight?. Issue Brief Natl Health Policy Forum. 2009;830:1–14
  41. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile associated diarrhea in a region of Quebec from 1991-2003; a changing pattern of disease severity. CMAJ. 2004;171:466–472
  42. Fenner L, Widmer AF, Goy G, et al. Rapid and reliable diagnostic algorithm for detection of Clostridium difficile. J Clin Microbiol. 2008;46:328–330
  43. Boyce JM. Hand hygiene compliance monitoring: Current perspectives from the USA. J Hosp Infect. 2008;70:2–7Oct
  44. Hooper DC. Emerging mechanisms of fluoroquinolone. Resistance. 2001;7(2):337–341
  45. Al Tureihi FJ, Hassoun A, Wolf-Klein G, et al. Albumin, length of stay and proton pump inhibitors: Key factors in Clostridium difficile associated disease in nursing home patients. J Am Med Dir Assoc. 2005;6:105–108
  46. Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid suppressive agents and the risk of community acquired Clostridium difficile associated disease. J Am Med Assoc. 2005;294:2989–2995
  47. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhea. J Hosp Infect. 2003;54:243–245
  48. Dallal RM, Harbrecht BG, Boujoukas AJ, et al. Fulminant Clostridium difficile an underappreciated and increasing cause of death and complications. Ann Surg. 2002;235:363–372
  49. Creedon SA. Healthcare workers' hand decontamination practices: Compliance with recommended guidelines. J Adv Nurs. 2005;51(;3):208–216
  50. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North American and Europe. Lancet. 2005;366:1079–1084
  51. McDonald LC, Killgore GE, Thompson A, et al. An epidemic toxin gene variant strain of Clostridium difficile. N Engl J Med. 2005;353:2433–2441
  52. Rupnik M, Brazier JS, Duertden BL, et al. Comparison of toxino-typing and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes. Microbiology. 2001;147:439–447
  53. Rupnik M, Kato N, Grabnar M, et al. New types of toxin A negative, toxin B positive strains among Clostridium difficile isolates from Asia. J Clin Microbiol. 2003;41:1118–1125
  54. Geric C, Rupnik M, Gerding DN, et al. Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin gene among clinical isolates in an American Hospital. J Med Microbiol. 2004;53:887–894
  55. McCannell DR, Louie TJ, Gregson DB, et al. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol. 2006;44:2147–2152
  56. Thomas C, Stevenson M, Riley T. Antibiotics and hospital acquired Clostridium difficile associated diarrhea: A systemic review. J Antimicrob Chemother. 2003;51(6):1339–1350
  57. Gerding DN, Jonson S, Peterson LR, et al. Clostridium difficile associated diarrhea and colitis. Infect Cont Hosp Epidemiol. 1995;16:459–477
  58. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile associated diarrhea and colitis. Am J Gastroenterol. 1997;92:739–750
  59. American Society of Health System Pharmacists ASHP. Therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile associated disease. Am J Health Syst Pharm. 1998;55:1407–1411
  60. Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Disord. 2001;32:331–351
  61. Flagyl (Metronidazole) Package Insert. Chicago, IL: Pharmacia; 2004;
  62. Vancocin (Vancomycin Hydrochloride) Package Insert. Exton, PA: ViroPharma; 2005;
  63. Teasley DG, Gerding DN, Olson MM, et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile associated diarrhea and colitis. Lancet. 1983;2:1043–1046
  64. Kelly CP, Pothoulakis C, LaMont IT. Clostridium difficile colitis. N Engl J Med. 1994;330:257
  65. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: Treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1770–1775
  66. In:  Kucers A,  Bennett NM editor. The Use of Antibiotics. 4th ed.. Philadelphia, PA: Lippincott; 1987;
  67. Wullt M, Odenholt I. A double blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile associated diarrhea. J Antimicrob Chemother. 2004;54:211–216
  68. De Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile associated diarrhea. Antimicrob Agents Chemother. 1992;36:2192–2196
  69. Wenisch C, Parschalk B, Hasenhundl M, et al. Comparison of vancomycin, teicoplanin, metronidazole and fusidic acid for the treatment of Clostridium difficile associated diarrhea. Clin Infect Dis. 1996;22:813–818[Erratum 1996:23:423]
  70. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007;44:846–848
  71. Taylor NS, Bartlett JG. Binding of Clostridium difficile cytotoxin and vancomycin by anion exchange resins. J Infect Dis. 1980;141:92–97
  72. Kruetzer EW, Milligan FD. Treatment of antibiotic associated pseudomembranous colitis with cholestyramine resin. Johns Hopkins Med J. 1978;143:67–72
  73. Scott VN, Taylor SL. Effect of nisin on the outgrowth of Clostridium botulinum spores. J Food Sci. 1981;46:117–120
  74. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390–397
  75. Naaber P, smidt I, Stsepetova J, et al. Inhibition of Clostridium difficile strains by intestinal lactobacillus species. J Med Microbiol. 2004;53:551–554
  76. Can M, Besirbellioglu BA, Avci IY, et al. Prophylactic Saccharomyces boulardii in the prevention of antibiotic associated diarrhea: A prospective study. Med Sci Monit. 2006;12:119–122
  77. Lewis S, Burmeister S, Brazier J. Effect of the probiotic oligofructose on relapse of Clostridium difficile associated diarrhea: A randomized controlled study. Clin Gastroenterol Hepatol. 2005;3:442–448
  78. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: Case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003;36:580–585
  79. Zigmund J. No more room; overcrowding blamed for ambulance diversions http://Modernhealthcare.com Available at: http://www.modernhealthcare.com/printwindow.cms?articleId=38689&pageType=article.
  80. Langmuir AD. Changing concepts of airborne infection of acute contagious diseases: a reconsideration of classic epidemiologic theories. Ann NY Acad Sci. 1980;353:35–44
  81. Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun. 2001;69:988–995
  82. Pechine S, Janoir C, Collignon A. Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile associated disease. J Clin Microbiol. 2005;43:5018–5025

PII: S0011-5029(09)00065-0

doi: 10.1016/j.disamonth.2009.04.010

Disease-A-Month
Volume 55, Issue 7 , Pages 439-470 , July 2009

Article Tools

* Image Usage & Resolution